Prof Wooseok Im
Translator — Korean
Articles translated into Korean by Prof Wooseok Im
- Hereditary Disease Foundation (HDF) conference 2022 – Day 1
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
- Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam
- Updates from uniQure about their gene therapy for Huntington's disease
- Artificial intelligence to save the day? How clever computers are helping us understand Huntington’s disease.
- A new roadmap to track Huntington’s disease progression
- Revisiting vitamin therapy for HD
- BAC to basics: a more accurate mouse model for Huntington's disease
- Shining a spotlight on huntingtin: a tool to measure huntingtin-lowering in real time
- Huntington’s disease therapeutics conference 2022 - Day 1
- Huntington’s disease therapeutics conference 2022 - Day 2
- Huntington’s disease therapeutics conference 2022 - Day 3
- A spoonful of branaplam helps the huntingtin go down
- Oral drug may change the story for huntingtin lowering
- Huntington's disease therapeutics conference 2021 - Day 2
- Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials
- Good news from uniQure: gene therapy trial on track, and promising data in animals
- Huntington’s disease clinical trial round up
- Huntington’s disease therapeutics conference 2021 - Day 1
- Huntington's disease therapeutics conference 2021 - Day 3
- Scientists identify precisely how pridopidine works in models of Huntington’s disease
- A first for CRISPR gene editing could have wider applications for human disease
- Does blood hold the key to testing treatments earlier in HD patients?
- Unpacking recent gene therapy press
- Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing
- Real talk: Q&A with Roche about GENERATION-HD1
- Updates from the EHDN Meeting 2021
- “Seeing” the toxic huntingtin protein in people with HD
- KINECT-HD trial shows valbenazine improves involuntary movements in Huntington's disease
- Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
- Huntington’s disease therapeutics conference 2020 - Day 1
- Huntington’s disease therapeutics conference 2020 - Day 2
- Vaccines and HD
- New molecule can reverse the Huntington's disease mutation in lab models
- GPR52: Exploring a new way to lower huntingtin
- What does COVID-19 mean for Huntington’s disease families and HD research?
- Fountain of youth: HTT protein repairs neurons by maintaining youthful state
- HD Young Adult Study defines the sweet spot: symptom-free with measurable changes
- Changing jobs: converting other cell types into neurons
- HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk
- Caution urged for the use of gene-editing technology CRISPR
- Working as a team: Changes in brain development mean some brain regions may be slacking off
- HDBuzz Enrolls in Enroll-HD
- Measuring harmful huntingtin protein in the brain’s bath water
- Uncovering the dark side of DNA repair to design HD treatments
- When genes are unstable: targeting somatic instability in HD
- Sad news from the SIGNAL study: pepinemab does not influence HD symptoms
- Updates from the EHDN Plenary Meeting 2020
- Treatment for neurological disorder could be repurposed for Huntington’s disease patients
- Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 1
- Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 2
- First Dolly, now Piglet; a new Huntington’s disease pig knock-in model confirmed
- New collaboration seeks to speed Huntington's disease drug licensing
- HDSA’s Q&A on the latest huntingtin-lowering update from Ionis and Roche
- Exciting Experiments in "Open Science" by Huntington's Researchers
- The structure of the protein that causes Huntington's disease, revealed
- Huntington's disease therapeutics conference 2018 - day 2
- Huntington's disease therapeutics conference 2018 - day 1
- Huntington's disease therapeutics conference 2018 - day 3
- An early role for the Huntington's disease gene – but don't believe all the headlines
- New interest in an old target
- Ask the expert: Q&A on the huntingtin-lowering trial program
- Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
- Switch off the genome editor when you’re done
- A new way of thinking about trials to prevent Huntington's disease
- New roles for huntingtin: removing a healthy protein to understand its function
- Precision huntingtin-lowering drug trials target the mutant protein
- A step forward for gene editing: CRISPR-Cas9 and HD
- New study reveals a potential HD biomarker
- Has a "wonder drug" for dementia been discovered? (Spoiler alert: no.)
- Huntington's Disease Therapeutics Conference 2017 - Day 3
- Huntington's Disease Therapeutics Conference 2017 - Day 2
- Huntington's Disease Therapeutics Conference 2017 - Day 1
- Update confirms Huntington's disease 'gene silencing' trial on track
- Enemy at the gates – huntingtin disrupts nuclear transport
- FDA approves a new drug for symptoms of Huntington's disease
- Sheep leading the flock: metabolism and biomarkers in HD
- Weeding out the truth: can cannabis improve Huntington’s?
- Huntingtin grabs a hammer: DNA repair in HD
- The benefits of migration, highlighted in Huntington's disease
- Treasure your exceptions - using outliers to understand Huntington's disease onset and progression
- Slightly long CAG repeats are more common than we thought
- A support system gone wrong - glial cells contribute to HD symptoms
- Deutetrabenazine for Huntington's disease: a positive trial but the FDA says no? Not exactly...
- Ultra-rare mutations highlight the importance of the HD gene in brain development
- Important advances in next generation genome editing tools for Huntington's Disease
- A powerful message: does a toxic RNA message molecule cause harm in Huntington's disease?
- Electron beam snaps best images yet of Huntington's disease protein
- Sorry folks, the PRIDE-HD trial did NOT show that Pridopidine slows the progression of Huntington's disease
- Through a Broader Lens: Looking at Non-Motor Symptoms in HD
- Huge study reveals new 'genetic modifiers' of Huntington's disease
- Pfizer Amaryllis trial ends in disappointment: no improvement in Huntington's disease symptoms